Bruker (BRKR) Financials

$42.88 -1.28 (-2.90%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$43.00 +0.12 (+0.28%)

As of 05/15/2026 05:59 PM Eastern

Annual Income Statements for Bruker

This table shows Bruker's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	102	154	79	180	197	158	277	297	427	113	-23
Consolidated Net Income / (Loss)	105	155	80	181	198	161	281	299	429	114	-8.30
Net Income / (Loss) Continuing Operations	105	155	80	181	499	161	281	299	429	114	-8.30
Total Pre-Tax Income	128	178	198	245	280	226	394	414	544	207	22
Total Operating Income	146	182	220	262	301	248	413	433	437	253	68
Total Gross Profit	709	745	816	900	995	940	1,210	1,306	1,513	1,650	1,578
Total Revenue	1,624	1,611	1,766	1,896	4,145	1,988	2,418	2,531	2,965	3,366	3,437
Operating Revenue	1,617	1,611	1,766	1,896	4,145	1,988	2,418	2,531	2,965	3,366	3,437
Total Cost of Revenue	915	866	950	996	2,155	1,048	1,208	1,225	1,451	1,717	1,859
Operating Cost of Revenue	915	866	950	996	2,155	-	1,208	1,225	1,451	1,717	1,859
Total Operating Expenses	563	564	597	638	1,389	692	796	873	1,076	1,396	1,510
Selling, General & Admin Expense	392	390	415	445	500	469	561	607	729	894	947
Research & Development Expense	146	148	162	173	188	198	221	236	295	377	395
Impairment Charge	-	-	-	-	-	-	-	-	0.00	0.00	97
Other Special Charges / (Income)	25	26	20	20	6.50	25	14	30	52	126	71
Total Other Income / (Expense), net	-18	-4.20	-22	-18	-21	-23	-20	-19	107	-46	-46
Other Income / (Expense), net	-18	-4.20	-22	-18	-21	-23	-20	-19	107	-46	-46
Income Tax Expense	23	23	118	64	82	64	113	116	118	91	29
Other Gains / (Losses), net	-	-	-	-	-	0.00	0.00	1.00	2.00	-1.70	-1.00
Preferred Stock Dividends Declared	-	-	-	-	-	-	-	-	0.00	0.00	14
Net Income / (Loss) Attributable to Noncontrolling Interest	3.30	0.90	1.70	1.30	0.80	3.60	3.50	1.90	1.30	0.70	0.30
Basic Earnings per Share	$0.60	$0.95	$0.50	$1.15	$1.27	$1.03	$1.83	$2.00	$2.92	$0.76	($0.15)
Weighted Average Basic Shares Outstanding	168.20M	161.40M	158.10M	156.20M	155.20M	153.40M	151.40M	148.60M	146.40M	149M	151.80M
Diluted Earnings per Share	$0.60	$0.95	$0.49	$1.14	$1.26	$1.02	$1.81	$1.99	$2.90	$0.76	($0.15)
Weighted Average Diluted Shares Outstanding	169.10M	162.20M	159.10M	157.20M	156.60M	154.60M	152.90M	149.40M	147.20M	149.50M	151.80M
Weighted Average Basic & Diluted Shares Outstanding	169.30M	161.70M	157.20M	156.30M	155.30M	151.57M	150.77M	146.73M	137.67M	151.71M	154.98M

This table shows Bruker's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	88	206	51	7.60	41	14	17	7.60	-62	15	3.50
Consolidated Net Income / (Loss)	89	205	52	7.60	40	14	17	4.20	-59	29	16
Net Income / (Loss) Continuing Operations	89	205	52	7.60	40	14	17	4.20	-59	29	16
Total Pre-Tax Income	119	241	72	24	55	56	25	0.50	-72	68	22
Total Operating Income	125	104	65	48	68	72	32	12	-52	76	10
Total Gross Profit	383	430	353	385	419	493	391	358	379	449	380
Total Revenue	743	855	722	801	864	980	801	797	861	977	823
Operating Revenue	743	855	722	801	864	980	801	797	861	977	823
Total Cost of Revenue	360	424	369	416	446	486	410	440	481	528	444
Operating Cost of Revenue	360	424	369	416	446	486	410	440	481	528	444
Total Operating Expenses	258	327	288	337	351	421	359	346	431	373	370
Selling, General & Admin Expense	178	211	195	221	230	247	225	231	243	247	242
Research & Development Expense	71	84	82	92	98	104	97	100	98	100	101
Other Special Charges / (Income)	9.40	32	11	23	23	70	37	14	-6.10	26	26
Total Other Income / (Expense), net	-5.30	137	6.80	-24	-13	-16	-6.70	-11	-20	-8.10	12
Other Income / (Expense), net	-5.30	137	6.80	-24	-13	-16	-6.70	-11	-20	-8.10	12
Income Tax Expense	31	37	20	16	15	41	8.70	-3.10	-14	38	2.50
Other Gains / (Losses), net	0.30	0.80	0.20	-0.20	-0.20	-1.50	0.40	0.60	-0.80	-1.20	-3.70
Preferred Stock Dividends Declared	-	-	-	-	0.00	-	0.00	-	2.80	-	11
Net Income / (Loss) Attributable to Noncontrolling Interest	0.60	-0.90	1.10	0.00	-0.60	0.20	-0.60	-3.40	1.10	3.20	1.30
Basic Earnings per Share	$0.60	$1.41	$0.35	$0.05	$0.27	$0.09	$0.11	$0.05	($0.41)	$0.10	$0.02
Weighted Average Basic Shares Outstanding	146.60M	146.40M	145.20M	147.40M	151.50M	149M	151.60M	151.60M	151.80M	151.80M	152.20M
Diluted Earnings per Share	$0.60	$1.39	$0.35	$0.05	$0.27	$0.09	$0.11	$0.05	($0.41)	$0.10	$0.02
Weighted Average Diluted Shares Outstanding	147.30M	147.20M	145.90M	148M	152M	149.50M	151.90M	151.70M	151.80M	151.80M	152.70M
Weighted Average Basic & Diluted Shares Outstanding	138.41M	137.67M	145.34M	151.39M	151.60M	151.71M	151.53M	151.72M	154.70M	154.98M	154.99M

This table details how cash moves in and out of Bruker's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-54	75	-17	3.90	356	3.60	386	-423	-157	-305	116
Net Cash From Operating Activities	229	131	154	240	213	332	282	274	350	251	134
Net Cash From Continuing Operating Activities	229	131	154	240	213	332	282	274	350	251	134
Net Income / (Loss) Continuing Operations	105	155	80	181	198	161	281	299	429	114	-8.30
Consolidated Net Income / (Loss)	105	155	80	181	198	161	281	299	429	114	-8.30
Depreciation Expense	53	54	64	65	76	80	89	89	115	184	220
Non-Cash Adjustments To Reconcile Net Income	54	34	-5.20	51	20	43	44	46	-81	136	171
Changes in Operating Assets and Liabilities, net	17	-112	15	-57	-80	47	-131	-159	-112	-183	-249
Net Cash From Investing Activities	-102	-22	-30	-123	-158	-193	-192	-252	-326	-1,757	-197
Net Cash From Continuing Investing Activities	-102	-22	-30	-123	-158	-193	-192	-252	-326	-1,757	-197
Purchase of Property, Plant & Equipment	-34	-37	-44	-49	-73	-97	-92	-129	-107	-115	-91
Acquisitions	-29	-24	-66	-192	-90	-59	-65	-182	-227	-1,600	-103
Purchase of Investments	-159	-127	-119	0.00	-6.40	-151	-149	-60	-25	-48	-7.20
Other Investing Activities, net	-	-	-	-	-	-	-	-	32	5.90	4.80
Net Cash From Financing Activities	-169	-28	-159	-112	300	-162	319	-415	-193	1,230	135
Net Cash From Continuing Financing Activities	-169	-28	-159	-112	300	-162	319	-415	-193	1,230	135
Repayment of Debt	-130	-0.10	-151	-223	-386	-305	-0.10	-111	-24	-1,348	-1,245
Repurchase of Common Equity	-90	-160	-152	0.00	-142	-123	-153	-263	-152	0.00	-10
Payment of Dividends	-1.30	-27	-26	-26	-25	-26	-24	-42	-29	-30	-33
Issuance of Debt	42	146	154	129	849	297	490	0.30	2.30	2,199	746
Issuance of Preferred Equity	-	-	-	-	-	-	-	-	0.00	0.00	670
Issuance of Common Equity	11	12	20	9.40	11	3.30	7.00	2.80	9.50	409	7.90
Effect of Exchange Rate Changes	-11	-6.40	18	-	0.60	26	-23	-31	12	-29	44
Cash Interest Paid	12	13	15	12	16	29	20	24	34	55	71
Cash Income Taxes Paid	57	72	53	61	61	43	146	147	97	154	223

This table details how cash moves in and out of Bruker's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-211	125	-148	-170	-22	35	1.00	-92	201	5.80	-166
Net Cash From Operating Activities	44	206	22	1.10	38	190	65	-128	-33	230	71
Net Cash From Continuing Operating Activities	44	206	22	1.10	38	190	65	-128	-33	230	71
Net Income / (Loss) Continuing Operations	89	205	52	7.60	40	14	17	4.20	-59	29	16
Consolidated Net Income / (Loss)	89	205	52	7.60	40	14	17	4.20	-59	29	16
Depreciation Expense	27	37	35	45	51	53	50	56	56	58	58
Non-Cash Adjustments To Reconcile Net Income	9.40	-121	0.60	27	16	52	-12	-12	114	58	21
Changes in Operating Assets and Liabilities, net	-81	84	-66	-79	-69	71	9.30	-176	-145	85	-24
Net Cash From Investing Activities	-155	-37	-304	-1,325	-68	-61	-26	-91	-24	-56	-40
Net Cash From Continuing Investing Activities	-155	-37	-304	-1,325	-68	-61	-26	-91	-24	-56	-40
Purchase of Property, Plant & Equipment	-27	-32	-21	-25	-33	-37	-26	-21	-21	-23	-24
Acquisitions	-120	-4.30	-275	-1,302	-0.20	-23	-1.10	-68	-0.20	-34	-16
Other Investing Activities, net	-	-	-8.30	-	-	-	1.00	-1.40	-2.70	7.90	0.50
Net Cash From Financing Activities	-93	-60	152	1,156	-2.70	-75	-51	96	258	-168	-205
Net Cash From Continuing Financing Activities	-93	-60	152	1,156	-2.70	-75	-51	96	258	-168	-205
Repayment of Debt	-2.50	-17	-108	-848	-155	-243	-176	-70	-868	-130	-181
Repurchase of Common Equity	-80	-50	0.00	-	-	-	-10	-	-	-	0.00
Payment of Dividends	-8.90	-7.80	-7.30	-7.80	-7.60	-21	-7.70	-7.60	-	-18	-19
Issuance of Debt	-3.40	10	263	805	-3.00	1,157	142	168	458	-24	-5.00
Effect of Exchange Rate Changes	-7.90	16	-18	-2.10	10	-19	13	32	-0.30	-0.90	7.90
Cash Interest Paid	-	-	-	-	-	-	13	-	15	21	11
Cash Income Taxes Paid	-	-	-	-	-	-	66	-	39	36	24

This table presents Bruker's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	1,730	1,808	1,949	2,129	2,772	3,049	3,650	3,612	4,250	5,807	6,241
Total Current Assets	1,232	1,276	1,359	1,304	1,796	1,925	2,472	2,113	2,164	2,053	2,213
Cash & Equivalents	267	342	325	322	678	682	1,068	646	488	183	299
Accounts Receivable	235	244	319	357	362	335	417	473	492	566	545
Inventories, net	422	440	486	510	577	692	710	800	968	1,068	1,095
Other Current Assets	107	91	114	115	172	166	177	195	216	237	274
Plant, Property, & Equipment, net	231	239	267	271	306	396	406	487	600	669	745
Total Noncurrent Assets	267	293	323	554	669	729	772	1,012	1,486	3,084	3,284
Goodwill	131	131	170	276	293	320	340	458	583	1,507	2,447
Other Noncurrent Operating Assets	9.10	17	14	8.40	82	107	131	206	276	378	837
Total Liabilities & Shareholders' Equity	1,730	1,808	1,949	2,129	2,772	3,049	3,650	3,612	4,250	5,807	6,241
Total Liabilities	997	1,115	1,215	1,201	1,833	2,075	2,565	2,480	2,837	3,992	3,731
Total Current Liabilities	555	525	525	599	646	792	939	914	1,202	1,281	1,279
Short-Term Debt	0.60	20	-	19	0.50	2.20	112	19	121	33	17
Accounts Payable	72	86	91	105	118	135	147	178	203	234	216
Current Deferred Revenue	178	149	112	124	138	189	198	370	400	438	441
Other Current Liabilities	304	270	322	352	389	466	481	347	478	577	605
Total Noncurrent Liabilities	443	591	691	602	1,188	1,283	1,627	1,566	1,635	2,710	2,452
Long-Term Debt	265	392	416	323	813	842	1,222	1,201	1,160	2,062	1,853
Other Noncurrent Operating Liabilities	32	40	96	137	161	223	204	156	315	430	599
Redeemable Noncontrolling Interest	-	-	-	23	21	0.00	0.20	6.10	19	18	37
Total Equity & Noncontrolling Interests	733	693	734	905	917	974	1,085	1,126	1,395	1,797	2,474
Total Preferred & Common Equity	726	686	725	897	907	961	1,071	1,114	1,377	1,781	0.00
Total Common Equity	726	686	725	897	907	961	1,071	1,114	1,377	1,781	0.00

This table presents Bruker's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	3,337	3,764	3,857	3,820	4,506	5,903	6,113	5,933	6,340	6,435	6,131
Total Current Assets	2,037	2,133	2,183	2,029	2,140	2,153	2,191	2,112	2,163	2,351	2,104
Cash & Equivalents	626	598	575	364	340	170	148	184	92	293	133
Accounts Receivable	421	472	451	485	475	507	538	538	523	551	543
Inventories, net	750	859	915	916	1,061	1,176	1,220	1,117	1,218	1,197	1,122
Other Current Assets	240	205	243	264	264	300	285	273	330	310	306
Plant, Property, & Equipment, net	422	511	523	527	586	657	694	689	759	747	720
Total Noncurrent Assets	879	1,120	1,151	1,263	1,780	3,093	3,228	3,133	3,419	3,338	3,308
Goodwill	382	527	558	561	752	1,444	1,475	2,435	2,619	2,469	2,475
Other Noncurrent Operating Assets	283	294	293	410	299	322	386	698	800	869	832
Total Liabilities & Shareholders' Equity	3,337	3,764	3,857	3,820	4,506	5,903	6,113	5,933	6,340	6,435	6,131
Total Liabilities	2,383	2,553	2,594	2,575	3,056	4,078	4,270	4,082	4,473	3,943	3,628
Total Current Liabilities	865	1,049	1,051	1,072	1,183	1,305	1,322	1,345	1,347	1,268	1,355
Short-Term Debt	17	120	121	121	21	26	33	38	56	24	8.40
Accounts Payable	158	196	189	182	199	220	228	245	243	184	269
Current Deferred Revenue	176	398	397	381	485	502	467	471	478	455	480
Other Current Liabilities	514	334	344	389	477	556	595	592	571	604	598
Total Noncurrent Liabilities	1,519	1,505	1,544	1,503	1,873	2,774	2,948	2,737	3,126	2,674	2,273
Long-Term Debt	1,137	1,109	1,123	1,099	1,357	2,132	2,265	2,076	2,380	1,984	1,663
Other Noncurrent Operating Liabilities	382	396	421	405	252	290	327	661	746	690	610
Redeemable Noncontrolling Interest	5.70	12	12	17	18	18	18	18	47	43	36
Total Equity & Noncontrolling Interests	948	1,199	1,251	1,227	1,433	1,807	1,825	1,833	1,819	2,450	2,467
Total Preferred & Common Equity	937	1,180	1,231	1,209	1,415	1,789	1,807	0.00	0.00	2,432	0.00
Total Common Equity	937	1,180	1,231	1,209	1,415	1,789	1,807	0.00	0.00	2,432	0.00

This table displays calculated financial ratios and metrics derived from Bruker's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	154,701,144.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	154,701,144.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.15
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	119	158	89	194	212	177	295	311	342	141	-23
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	13.26%	12.80%	3.63%	-0.52%
Earnings before Interest and Taxes (EBIT)	128	178	198	245	280	226	394	414	544	207	22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	181	232	262	310	356	306	483	503	659	391	242
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	218	84	-16	-42	92	157	131	-144	-159	-1,378	-377
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	530	605	710	946	1,067	1,087	1,251	1,706	2,207	3,726	4,081
Increase / (Decrease) in Invested Capital	-99	74	105	237	120	20	164	455	501	1,520	355
Book Value per Share	$4.33	$4.28	$4.66	$5.73	$5.89	$6.28	$7.06	$7.57	$9.95	$11.75	$15.88
Tangible Book Value per Share	$3.10	$3.03	$3.04	$2.57	$2.47	$2.69	$3.42	$2.62	$3.35	($4.21)	$0.06
Total Capital	999	1,105	1,149	1,269	1,752	1,819	2,419	2,351	2,695	3,910	4,379
Total Debt	266	412	416	341	813	845	1,334	1,219	1,282	2,094	1,869
Total Long-Term Debt	265	392	416	323	813	842	1,222	1,201	1,160	2,062	1,853
Net Debt	-203	-89	-24	19	128	113	166	574	793	1,911	1,570
Capital Expenditures (CapEx)	33	36	32	49	62	97	87	115	96	114	91
Debt-free, Cash-free Net Working Capital (DFCFNWC)	209	271	395	401	466	404	478	572	595	621	651
Debt-free Net Working Capital (DFNWC)	678	771	834	724	1,151	1,135	1,646	1,218	1,083	804	950
Net Working Capital (NWC)	677	751	834	705	1,151	1,133	1,533	1,199	962	772	933
Net Nonoperating Expense (NNE)	15	3.65	8.81	13	14	16	14	13	-86	27	-14
Net Nonoperating Obligations (NNO)	-203	-89	-24	19	128	113	166	574	793	1,911	1,570
Total Depreciation and Amortization (D&A)	53	54	64	65	76	80	89	89	115	184	220
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.60	$0.95	$0.50	$1.15	$1.27	$1.03	$1.83	$2.00	$2.92	$0.76	($0.15)
Adjusted Weighted Average Basic Shares Outstanding	168.20M	161.40M	158.10M	156.20M	155.20M	153.40M	151.40M	148.60M	146.40M	149M	151.80M
Adjusted Diluted Earnings per Share	$0.60	$0.95	$0.49	$1.14	$1.26	$1.02	$1.81	$1.99	$2.90	$0.76	($0.15)
Adjusted Weighted Average Diluted Shares Outstanding	169.10M	162.20M	159.10M	157.20M	156.60M	154.60M	152.90M	149.40M	147.20M	149.50M	151.80M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$1.27	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	163.42M	159.88M	156.01M	156.74M	155.30M	151.57M	150.77M	146.73M	137.67M	151.71M	154.98M
Normalized Net Operating Profit after Tax (NOPAT)	140	181	167	209	217	195	305	332	383	212	165
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Bruker's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	154,701,144.00	154,979,250.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	154,701,144.00	154,979,250.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	0.10	0.02
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	16.26%	20.62%	5.31%	17.42%	16.37%	14.64%	11.04%	-0.41%	-0.45%	-	2.75%
EBITDA Growth	-2.99%	91.20%	-19.29%	-33.17%	-27.09%	-60.82%	-28.97%	-18.09%	-115.15%	-	6.23%
EBIT Growth	-7.81%	99.09%	-32.83%	-69.16%	-53.61%	-76.71%	-64.94%	-97.91%	-229.84%	-	-12.75%
NOPAT Growth	3.21%	-17.13%	-46.90%	-75.50%	-45.98%	-77.40%	-55.68%	445.81%	-172.70%	-	-56.51%
Net Income Growth	0.34%	108.14%	-32.82%	-86.85%	-54.57%	-93.21%	-67.69%	-44.74%	-245.16%	-	-6.55%
EPS Growth	1.69%	110.61%	-32.69%	-87.18%	-55.00%	-93.53%	-68.57%	0.00%	-251.85%	-	-81.82%
Operating Cash Flow Growth	-36.55%	19.83%	-75.09%	-91.54%	-12.93%	-7.54%	198.17%	-11,690.91%	-186.46%	-	9.54%
Free Cash Flow Firm Growth	-263.81%	-18.45%	-44.55%	-350.33%	-249.85%	-262.76%	-111.69%	83.32%	86.33%	-	80.26%
Invested Capital Growth	41.78%	29.38%	35.14%	97.45%	90.09%	68.87%	51.89%	10.41%	5.40%	-	6.87%
Revenue Q/Q Growth	8.93%	15.04%	-15.54%	10.95%	7.96%	13.33%	-18.19%	-0.50%	7.91%	-	-15.74%
EBITDA Q/Q Growth	41.01%	90.81%	-61.79%	-35.00%	53.84%	2.54%	-30.73%	-25.03%	-128.45%	-	-36.50%
EBIT Q/Q Growth	53.81%	102.10%	-70.28%	-66.62%	131.38%	1.45%	-55.26%	-98.01%	-14,460.00%	-	-67.89%
NOPAT Q/Q Growth	44.12%	-5.17%	-46.46%	-66.52%	217.71%	-60.32%	4.98%	312.37%	-142.32%	-	-73.43%
Net Income Q/Q Growth	53.46%	130.67%	-74.58%	-85.38%	430.26%	-65.51%	20.86%	-75.00%	-1,492.86%	-	-46.23%
EPS Q/Q Growth	53.85%	131.67%	-74.82%	-85.71%	440.00%	-66.67%	22.22%	-54.55%	-920.00%	-	-80.00%
Operating Cash Flow Q/Q Growth	239.23%	365.99%	-89.39%	-94.95%	3,390.91%	394.79%	-65.79%	-296.15%	73.96%	-	-69.02%
Free Cash Flow Firm Q/Q Growth	-27.06%	21.48%	-45.20%	-210.88%	1.29%	18.59%	15.27%	75.51%	19.11%	-	21.72%
Invested Capital Q/Q Growth	8.75%	5.06%	12.81%	53.19%	4.70%	-6.67%	1.47%	11.35%	-0.05%	-	-0.98%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	51.53%	50.36%	48.88%	48.03%	48.45%	50.36%	48.81%	44.88%	44.09%	-	46.13%
EBITDA Margin	19.63%	32.56%	14.73%	8.63%	12.30%	11.13%	9.42%	7.10%	-1.87%	-	9.74%
Operating Margin	16.76%	12.11%	8.98%	6.01%	7.88%	7.36%	3.97%	1.49%	-6.02%	-	1.24%
EBIT Margin	16.05%	28.19%	9.92%	2.98%	6.40%	5.73%	3.13%	0.06%	-8.34%	-	2.66%
Profit (Net Income) Margin	11.94%	23.94%	7.21%	0.95%	4.66%	1.42%	2.10%	0.53%	-6.80%	-	1.91%
Tax Burden Percent	74.41%	84.93%	72.63%	31.80%	72.88%	24.78%	66.93%	840.00%	81.48%	-	71.69%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-	100.00%
Effective Tax Rate	25.84%	15.40%	27.65%	67.36%	26.76%	72.55%	34.66%	-620.00%	0.00%	-	11.42%
Return on Invested Capital (ROIC)	19.56%	15.53%	9.00%	2.13%	6.14%	2.29%	2.85%	9.22%	-3.53%	-	0.97%
ROIC Less NNEP Spread (ROIC-NNEP)	19.04%	32.66%	9.61%	1.52%	5.50%	1.86%	2.58%	5.46%	-4.69%	-	1.35%
Return on Net Nonoperating Assets (RNNOA)	11.98%	17.54%	6.03%	1.31%	5.36%	1.56%	2.32%	6.41%	-4.18%	-	1.08%
Return on Equity (ROE)	31.55%	33.07%	15.03%	3.44%	11.50%	3.85%	5.17%	15.63%	-7.71%	-	2.05%
Cash Return on Invested Capital (CROIC)	-14.98%	-8.11%	-16.08%	-56.36%	-54.87%	-46.47%	-37.69%	-7.35%	-8.77%	-	-6.92%
Operating Return on Assets (OROA)	12.64%	21.26%	7.20%	1.91%	4.18%	3.83%	2.07%	0.04%	-4.57%	-	1.53%
Return on Assets (ROA)	9.41%	18.06%	5.23%	0.61%	3.04%	0.95%	1.38%	0.30%	-3.73%	-	1.09%
Return on Common Equity (ROCE)	30.80%	32.37%	14.66%	3.36%	11.23%	3.76%	2.22%	7.58%	-7.54%	-	0.00%
Return on Equity Simple (ROE_SIMPLE)	26.65%	0.00%	28.48%	19.72%	16.85%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Net Operating Profit after Tax (NOPAT)	92	88	47	16	50	20	21	86	-36	34	9.04
NOPAT Margin	12.43%	10.25%	6.50%	1.96%	5.77%	2.02%	2.59%	10.74%	-4.21%	-	1.10%
Net Nonoperating Expense Percent (NNEP)	0.52%	-17.12%	-0.61%	0.61%	0.64%	0.44%	0.27%	3.76%	1.15%	-	-0.38%
Return On Investment Capital (ROIC_SIMPLE)	-	3.27%	-	-	-	0.51%	0.53%	2.01%	-0.81%	0.78%	0.22%
Cost of Revenue to Revenue	48.47%	49.64%	51.12%	51.97%	51.55%	49.64%	51.19%	55.12%	55.91%	-	53.87%
SG&A Expenses to Revenue	23.91%	24.72%	27.06%	27.64%	26.60%	25.25%	28.13%	29.02%	28.18%	-	29.40%
R&D to Revenue	9.60%	9.77%	11.33%	11.51%	11.35%	10.66%	12.12%	12.57%	11.42%	-	12.30%
Operating Expenses to Revenue	34.77%	38.24%	39.91%	42.03%	40.57%	43.00%	44.85%	43.39%	50.11%	-	44.89%
Earnings before Interest and Taxes (EBIT)	119	241	72	24	55	56	25	0.50	-72	68	22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	146	278	106	69	106	109	76	57	-16	126	80
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.55	7.36	9.13	5.18	5.79	4.99	0.00	0.00	2.03	-	0.00
Price to Tangible Book Value (P/TBV)	25.64	21.85	60.33	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Price to Revenue (P/Rev)	3.24	3.42	4.31	2.97	3.23	2.64	1.84	1.81	1.43	-	1.62
Price to Earnings (P/E)	28.59	23.74	32.18	26.34	34.29	78.57	79.55	78.43	0.00	-	0.00
Dividend Yield	0.32%	0.27%	0.21%	0.31%	0.29%	0.34%	0.48%	0.49%	0.62%	-	0.55%
Earnings Yield	3.50%	4.21%	3.11%	3.80%	2.92%	1.27%	1.26%	1.28%	0.00%	-	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.77	4.97	5.62	2.96	3.17	2.91	2.19	2.05	1.59	-	1.77
Enterprise Value to Revenue (EV/Rev)	3.55	3.70	4.66	3.62	3.90	3.22	2.40	2.51	1.95	-	2.07
Enterprise Value to EBITDA (EV/EBITDA)	19.02	16.64	22.09	18.85	22.58	27.72	23.01	24.85	29.80	-	29.03
Enterprise Value to EBIT (EV/EBIT)	23.60	20.16	27.49	24.80	32.27	52.35	51.62	63.02	677.30	-	381.47
Enterprise Value to NOPAT (EV/NOPAT)	28.57	32.04	46.83	42.92	57.27	76.66	75.33	84.74	0.00	-	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	31.68	31.33	49.22	41.46	47.38	43.10	28.12	52.04	71.11	-	51.12
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.98	0.91	0.95	1.18	1.25	1.15	1.14	1.30	0.81	-	0.67
Long-Term Debt to Equity	0.88	0.82	0.94	1.17	1.23	1.14	1.12	1.27	0.80	-	0.66
Financial Leverage	0.63	0.54	0.63	0.86	0.97	0.84	0.90	1.17	0.89	-	0.80
Leverage Ratio	3.26	3.09	3.11	3.16	3.22	3.11	3.16	3.32	2.89	-	2.77
Compound Leverage Factor	3.26	3.09	3.11	3.16	3.22	3.11	3.16	3.32	2.89	-	2.77
Debt to Total Capital	49.50%	47.55%	48.72%	54.19%	55.49%	53.57%	53.31%	56.61%	44.62%	-	40.04%
Short-Term Debt to Total Capital	4.91%	4.50%	0.75%	0.66%	0.79%	0.83%	0.95%	1.29%	0.54%	-	0.20%
Long-Term Debt to Total Capital	44.59%	43.06%	47.97%	53.53%	54.69%	52.74%	52.36%	55.31%	44.08%	-	39.84%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Noncontrolling Interests to Total Capital	1.44%	1.34%	1.25%	0.89%	0.87%	0.87%	0.46%	1.10%	1.34%	-	0.86%
Common Equity to Total Capital	49.06%	51.11%	50.02%	44.92%	43.64%	45.56%	0.00%	0.00%	54.03%	-	0.00%
Debt to EBITDA	2.32	1.94	2.18	3.60	4.10	5.36	5.87	7.01	8.93	-	6.77
Net Debt to EBITDA	1.63	1.20	1.64	3.32	3.84	4.89	5.36	6.75	7.62	-	6.23
Long-Term Debt to EBITDA	2.09	1.76	2.14	3.56	4.04	5.28	5.77	6.85	8.82	-	6.73
Debt to NOPAT	3.48	3.74	4.61	8.20	10.41	14.82	19.23	23.90	-13.93	-	-156.80
Net Debt to NOPAT	2.44	2.32	3.47	7.55	9.74	13.52	17.56	23.00	-11.90	-	-144.29
Long-Term Debt to NOPAT	3.13	3.39	4.54	8.10	10.26	14.59	18.89	23.36	-13.76	-	-156.02
Altman Z-Score	3.27	4.07	4.25	2.64	2.75	2.69	1.68	1.54	1.96	-	1.65
Noncontrolling Interest Sharing Ratio	2.37%	2.13%	2.48%	2.16%	2.32%	2.17%	57.14%	51.53%	2.23%	-	100.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.89	1.80	1.81	1.65	1.66	1.60	1.57	1.61	1.85	-	1.55
Quick Ratio	0.79	0.82	0.69	0.52	0.52	0.58	0.54	0.46	0.67	-	0.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-527	-413	-600	-1,866	-1,842	-1,500	-1,271	-311	-252	-320	-251
Operating Cash Flow to CapEx	165.17%	656.55%	104.31%	4.55%	117.79%	520.55%	250.00%	-598.59%	-158.85%	-	294.21%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.79	0.75	0.73	0.64	0.65	0.67	0.66	0.56	0.55	-	0.57
Accounts Receivable Turnover	6.22	6.15	6.34	6.51	6.33	6.37	6.80	6.69	6.31	-	6.40
Inventory Turnover	1.64	1.64	1.56	1.50	1.55	1.69	1.62	1.49	1.50	-	1.69
Fixed Asset Turnover	5.94	5.46	5.47	5.29	5.31	5.31	5.41	4.87	4.77	-	4.91
Accounts Payable Turnover	8.07	7.62	7.56	7.67	8.09	7.86	7.93	7.69	8.82	-	7.37
Days Sales Outstanding (DSO)	58.71	59.39	57.60	56.04	57.64	57.33	53.66	54.59	57.81	-	57.02
Days Inventory Outstanding (DIO)	221.95	222.39	234.37	243.13	235.61	216.43	225.97	245.25	242.75	-	215.85
Days Payable Outstanding (DPO)	45.20	47.93	48.27	47.58	45.11	46.43	46.06	47.46	41.37	-	49.55
Cash Conversion Cycle (CCC)	235.45	233.85	243.70	251.59	248.15	227.33	233.57	252.38	259.19	-	223.32
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,100	2,207	2,489	3,813	3,992	3,726	3,781	4,210	4,208	4,081	4,041
Invested Capital Turnover	1.57	1.52	1.39	1.09	1.06	1.13	1.10	0.86	0.84	-	0.88
Increase / (Decrease) in Invested Capital	619	501	647	1,882	1,892	1,520	1,292	397	216	355	260
Enterprise Value (EV)	10,014	10,970	13,997	11,298	12,641	10,832	8,280	8,634	6,705	-	7,172
Market Capitalization	9,123	10,141	12,923	9,274	10,455	8,887	6,332	6,243	4,929	-	5,598
Book Value per Share	$8.23	$9.95	$10.28	$12.31	$11.94	$11.75	$0.00	$0.00	$16.03	$15.88	$0.00
Tangible Book Value per Share	$2.42	$3.35	$1.56	($4.67)	($4.58)	($4.21)	($16.05)	($17.28)	($0.24)	$0.06	($15.97)
Total Capital	2,464	2,695	2,829	3,983	4,140	3,910	3,965	4,302	4,501	4,379	4,174
Total Debt	1,220	1,282	1,379	2,158	2,297	2,094	2,114	2,435	2,009	1,869	1,671
Total Long-Term Debt	1,099	1,160	1,357	2,132	2,265	2,062	2,076	2,380	1,984	1,853	1,663
Net Debt	856	793	1,038	1,989	2,149	1,911	1,930	2,343	1,715	1,570	1,538
Capital Expenditures (CapEx)	27	31	21	24	33	37	26	21	21	23	24
Debt-free, Cash-free Net Working Capital (DFCFNWC)	715	595	639	705	754	621	620	779	814	651	624
Debt-free Net Working Capital (DFNWC)	1,078	1,083	979	875	902	804	804	871	1,107	950	757
Net Working Capital (NWC)	957	962	958	849	869	772	767	815	1,083	933	749
Net Nonoperating Expense (NNE)	3.63	-117	-5.12	8.10	9.57	5.89	3.98	81	22	4.81	-6.66
Net Nonoperating Obligations (NNO)	856	793	1,038	1,989	2,149	1,911	1,930	2,343	1,715	1,570	1,538
Total Depreciation and Amortization (D&A)	27	37	35	45	51	53	50	56	56	58	58
Debt-free, Cash-free Net Working Capital to Revenue	25.35%	20.07%	21.29%	22.60%	23.26%	18.45%	17.99%	22.63%	23.66%	-	18.03%
Debt-free Net Working Capital to Revenue	38.25%	36.54%	32.63%	28.04%	27.83%	23.90%	23.34%	25.30%	32.18%	-	21.89%
Net Working Capital to Revenue	33.96%	32.45%	31.92%	27.20%	26.82%	22.93%	22.25%	23.68%	31.48%	-	21.64%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.60	$1.41	$0.35	$0.05	$0.27	$0.09	$0.11	$0.05	($0.41)	$0.10	$0.02
Adjusted Weighted Average Basic Shares Outstanding	146.60M	146.40M	145.20M	147.40M	151.50M	149M	151.60M	151.60M	151.80M	151.80M	152.20M
Adjusted Diluted Earnings per Share	$0.60	$1.39	$0.35	$0.05	$0.27	$0.09	$0.11	$0.05	($0.41)	$0.10	$0.02
Adjusted Weighted Average Diluted Shares Outstanding	147.30M	147.20M	145.90M	148M	152M	149.50M	151.90M	151.70M	151.80M	151.80M	152.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	138.41M	137.67M	145.34M	151.39M	151.60M	151.71M	151.53M	151.72M	154.70M	154.98M	154.99M
Normalized Net Operating Profit after Tax (NOPAT)	99	115	55	50	66	99	45	18	27	72	32
Normalized NOPAT Margin	13.37%	13.43%	7.59%	6.22%	7.69%	10.12%	5.60%	2.31%	3.14%	-	3.92%
Pre Tax Income Margin	16.05%	28.19%	9.92%	2.98%	6.40%	5.73%	3.13%	0.06%	-8.34%	-	2.66%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	8.44%	6.16%	8.06%	9.27%	10.31%	39.46%	57.63%	60.11%	-159.32%	-	-465.96%
Augmented Payout Ratio	48.23%	41.70%	40.29%	46.08%	26.86%	39.46%	70.36%	73.40%	-201.69%	-	-465.96%

Financials Breakdown Chart

Key Financial Trends

Here are the most notable trends from Bruker (BRKR) across the last four years of quarterly statements, focused on revenue, profitability, cash flow, and balance sheet strength.

Net income from continuing operations in Q4 2025 was $29.2 million, returning to positive profitability after a weaker Q3 period.
Operating cash flow from continuing operations in Q4 2025 was $229.8 million, underscoring strong cash generation despite quarterly volatility.
Balance sheet liquidity remained solid in late-2025, with total current assets of about $2.35 billion and total current liabilities of about $1.27 billion, yielding a rough 1.85x current ratio.
R&D spending remained high, at roughly $100 million per quarter (Q4 2025: $99.6 million; Q3 2025: $98.3 million), indicating ongoing investment in product development.
Total assets around $6.43 billion and total equity near $2.44 billion (as of Q3 2025) reflect a solid capital base to support ongoing operations.
Goodwill (~$2.47 billion) and intangible assets (~$0.87 billion) remain significant components of noncurrent assets, highlighting past acquisitions and IP value.
Financing activity showed variability: a positive net cash from financing activities of about $258 million in Q3 2025, followed by a negative $167.6 million in Q4 2025, indicating access to capital markets but changing near-term funding flows.
Impairment charge in Q3 2025 was $96.5 million, contributing to a quarterly net loss and weighing on profitability metrics.
Q3 2025 also showed a net loss from continuing operations of $58.5 million and a negative quarterly cash flow from operating activities of about $33.2 million, signaling a period of stress that offset other improvements.
Gross margin compression occurred in Q4 2025 (about 45.9% gross margin on $977.2 million revenue) versus higher margins in prior periods, indicating margin pressure that could affect profitability trajectory if sustained.

05/17/26 06:40 PM ETAI Generated. May Contain Errors.

Bruker Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Bruker's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Bruker's net income appears to be on an upward trend, with a most recent value of -$8.30 million in 2025, falling from $104.90 million in 2015. The previous period was $113.80 million in 2024. See Bruker's forecast for analyst expectations on what's next for the company.

Bruker's total operating income in 2025 was $68.20 million, based on the following breakdown:

Total Gross Profit: $1.58 billion
Total Operating Expenses: $1.51 billion

Over the last 10 years, Bruker's total revenue changed from $1.62 billion in 2015 to $3.44 billion in 2025, a change of 111.6%.

Bruker's total liabilities were at $3.73 billion at the end of 2025, a 6.5% decrease from 2024, and a 274.2% increase since 2015.

In the past 10 years, Bruker's cash and equivalents has ranged from $183.40 million in 2024 to $1.07 billion in 2021, and is currently $298.80 million as of their latest financial filing in 2025.

Over the last 10 years, Bruker's book value per share changed from 4.33 in 2015 to 15.88 in 2025, a change of 267.1%.

Related Companies

Financial statements for NASDAQ:BRKR last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bruker (BRKR) Financials

Financials Breakdown Chart

Key Financial Trends

Bruker Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bruker (BRKR) Financials

Annual Income Statements for Bruker

Quarterly Income Statements for Bruker

Annual Cash Flow Statements for Bruker

Quarterly Cash Flow Statements for Bruker

Annual Balance Sheets for Bruker

Quarterly Balance Sheets for Bruker

Annual Metrics And Ratios for Bruker

Quarterly Metrics And Ratios for Bruker

Financials Breakdown Chart

Key Financial Trends

Bruker Financials - Frequently Asked Questions

When does Bruker's fiscal year end?

How has Bruker's net income changed over the last 10 years?

What is Bruker's operating income?

How has Bruker's revenue changed over the last 10 years?

How much debt does Bruker have?

How much cash does Bruker have?

How has Bruker's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools